retatrutide phase 2 obesity trial results ly3437943 nejm 2023 Incretin triple agonist (LY3437943) alleviates obesity-associated cancer progression Retatrutide Availability & Timeline Flavor:Dynamic Duo concern_weight_metab Central GLP-1 contributes to

retatrutide phase 2 obesity trial results ly3437943 nejm 2023 Incretin triple agonist (LY3437943) alleviates obesity-associated cancer progression Retatrutide Availability & Timeline Flavor:Dynamic Duo concern_weight_metab Central GLP-1 contributes to

Central GLP-1 contributes to improved cognitive function and brain glucose uptake after duodenum-jejunum bypass on obese and diabetic rats | American Journal of Physiology-Endocrinology and Metabolism | American Physiological Society

Its 2025 GLP-1/GIP license (Hansoh’s HS-20094) ( [2] ) and pipeline of muscle-preserving therapies (Trevogrumab, etc.) illustrate a multipronged obesity strategy

concern_weight_metab

Flavor:Dynamic Duo

They reduced their training volume without abandoning intensity